ArticleExperimental & molecular medicine2017
Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer.
Article in Experimental & molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Ethanol extract fromNarra J · 2025Article
- LINC00673 binds with leptin to regulate osteogenic function in periodontal ligament stem cells.Journal of orthopaedic surgery and research · 2025Article
- Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.Nature reviews. Urology · 2025Review
- Article
- Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.International urology and nephrology · 2022Article
- Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer.Frontiers in cell and developmental biology · 2022Article
- Copy number variation analysis of mCancer medicine · 2021Article
- Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer.Frontiers in oncology · 2021Article
- Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy.Scientific reports · 2020Article
- Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist.Investigative and clinical urology · 2020Review
- Latent periodic process inference from single-cell RNA-seq data.Nature communications · 2020Article
- PBK as a Potential Biomarker Associated with Prognosis of Glioblastoma.Journal of molecular neuroscience : MN · 2020Article
- Identification of an immunotherapy-responsive molecular subtype of bladder cancer.EBioMedicine · 2019Article
- Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.Journal of experimental & clinical cancer research : CR · 2019Article
- Article
- Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin.Bioscience reports · 2019Article
- Comprehensive Gene Expression Analysis in NMIBC Using RNA-seq Reveals New Therapy Strategies.Frontiers in oncology · 2019Article
- A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma.Experimental & molecular medicine · 2018Article
- Prognostic Values ofJournal of Cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-muscle invasive bladder cancer (NMIBC) patients frequently fail to respond to treatment and experience disease progression because of their clinical and biological diversity. In this study, we identify a prognostic molecular signature for predicting the heterogeneity of NMIBC by using an integrative analysis of copy number and gene expression data. We analyzed the copy number and gene expression profiles of 404 patients with bladder cancer obtained from The Cancer Genome Atlas (TCGA) consortium. Of the 14 molecules with significant copy number alterations that were previously reported, 13 were significantly correlated with copy number and expression changes. Prognostic gene sets based on the 13 genes were developed, and their prognostic values were verified in three independent patient cohorts (n=501). Among them, a signature of CCNE1 and its coexpressed genes was significantly associated with disease progression and validated in the independent cohorts. The CCNE1 signature was an independent risk factor based on the result of a multivariate analysis (hazard ratio=6.849, 95% confidence interval=1.613-29.092, P=0.009). Finally, gene network and upstream regulator analyses revealed that NMIBC progression is potentially mediated by CCND1-CCNE1-SP1 pathways. The prognostic molecular signature defined by copy number and expression changes of CCNE1 suggests a novel diagnostic tool for predicting the likelihood of NMIBC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.